A 16-Year Multi-Institutional Study of the Role of Age and EBV Status on PTLD Incidence Among Pediatric Heart Transplant Recipients

2012 ◽  
Vol 12 (11) ◽  
pp. 3061-3068 ◽  
Author(s):  
R. Chinnock ◽  
S. A. Webber ◽  
A. I. Dipchand ◽  
R. N. Brown ◽  
J. F. George ◽  
...  
2017 ◽  
Vol 22 (5) ◽  
pp. 378-381 ◽  
Author(s):  
Adele King ◽  
Aymen Naguib ◽  
Joseph D. Tobias

Sugammadex is a novel pharmacologic agent that is used to selectively reverse the effects of the neuromuscular blocking agents rocuronium and vecuronium. Various advantages have been reported when comparing its reversal of neuromuscular blockade to that achieved with acetylcholinesterase inhibitors (neostigmine). In heart transplant recipients, bradycardia may occur following the administration of acetylcholinesterase inhibitors, due to the denervation of the heart. Theoretically, the combination of rocuronium and sugammadex could be advantageous in this clinical scenario to avoid the potential bradycardia resulting from neostigmine administration. We present a 10-year-old male who developed profound bradycardia immediately following the administration of intravenous sugammadex. The options for reversal of neuromuscular blockade in heart transplant recipients is discussed, previous reports of bradycardia following sugammadex are presented, and the role of sugammadex in the bradycardia in our patient is reviewed.


2016 ◽  
Vol 35 (4) ◽  
pp. S75
Author(s):  
A. Joong ◽  
M.E. Richmond ◽  
K.O. Stack ◽  
R.J. Rodriguez ◽  
J.M. McAllister ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document